Vestar is searching for partners to help market its three diagnosticimaging agents, which use liposome-based targeting technology.The San Dimas, CA, firm had early success in clinical trials withits therapeutic drugs and has been developing a sales force
Vestar is searching for partners to help market its three diagnosticimaging agents, which use liposome-based targeting technology.The San Dimas, CA, firm had early success in clinical trials withits therapeutic drugs and has been developing a sales force tohandle therapeutic sales, said Dr. Paul G. Schmidt, executivevice president of research and development.
Liposome Co., a liposome competitor, filed a patent infringementsuit against Vestar in June related to the company's antifungalagent for AIDS and cancer patients. This litigation has had noeffect on Vestar's effort to license its diagnostic imaging agents,Schmidt said.
In Vestar's development pipeline are three imaging agents inadvanced stages:
Vestar has worked with outside companies in the past, includingMallinckrodt, which was chosen four years ago to market productsin select European markets (SCAN 2/17/88).
The small firm hopes to line up a similar partner experiencedin imaging-agent sales to take over sales of the three agents.Vestar will maintain basic technology and manufacturing rights,Schmidt said.
"We would be licensing broadly across indications, butwe intend to retain aspects of the technology, such as manufacturing,"he told SCAN.
Vestar has been developing protocols for use of diagnosticand therapeutic liposome agents in combination, he said.
"The diagnostic (agent) is very similar to the therapeuticcontaining liposome. It could therefore be used in conjunctionwith the therapeutic for better predictive abilities," hesaid.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.